Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes
Introduction We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD).Material and methods Consecutive patients with type 2 diabetes and CAD were prospectively included from 03/2019 to 12/2020.Results LADIES ACCESSORIES HATS 574 patients were included; mean age 71 years, 81% males, with a high prevalence of oth